Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2025 02:40 ET | Source: Cellectis Inc.

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
September 05, 2025 10:39 ET | Source: Research and Markets

$5.1 Bn Chimeric Antigen Receptor (CAR) T-cell Therapy Market Analysis by Indication, Cell Source, Generation, Line Of Therapy, Target Antigen, End User - Global Forecast to 2030

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy Market by Indication (Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma), Cell Source (Allogeneic, Autologous), Generation, Line Of...
September 03, 2025 16:30 ET | Source: Cellectis Inc.

Monthly information on share capital and company voting rights

PARIS, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
September 03, 2025 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving...
August 04, 2025 16:30 ET | Source: Cellectis Inc.

Cellectis publie ses résultats financiers du deuxième trimestre 2025 et une mise à jour de ses activités

Cellectis organise un R&D Day dédié aux investisseurs à New York le 16 octobre 2025 : les données de phase 1 et la stratégie de développement de lasmé-cel (UCART22) dans la LAL-B r/r y seront...
August 04, 2025 16:30 ET | Source: Cellectis Inc.

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1...
July 28, 2025 16:30 ET | Source: Cellectis Inc.

Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
July 25, 2025 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with...
July 24, 2025 04:20 ET | Source: Research and Markets

CAR T-Cell Therapy Market Trends and Forecasts, 2021-2024 & 2025-2033 | Focus on Yescarta, Tecartus, Kymriah, Breyanzi, Abecma, Carvykti, and Carteyva

Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033" report has been added to ResearchAndMarkets.com's offering. The...
July 08, 2025 06:00 ET | Source: Cargo Therapeutics, Inc.

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right